Go to Polygence Scholars page
Linda Tewodros Mazengia's cover illustration
Polygence Scholar2024
Linda Tewodros Mazengia's profile

Linda Tewodros Mazengia

Class of 2024South Wales, Wales



  • "Exploring the Effectiveness of Gene Therapies and Personalized Medicine for Autism Spectrum Disorder" with mentor Carmen (Jan. 5, 2024)

Linda Tewodros' Symposium Presentation

Project Portfolio

Exploring the Effectiveness of Gene Therapies and Personalized Medicine for Autism Spectrum Disorder

Started Sept. 7, 2023

Abstract or project description

Autism Spectrum Disorder (ASD), a complex neurodevelopmental disorder affecting 1.5% of the population, is characterized by its complex etiology involving genetic, environmental, and neurological factors. ASD has a spectrum nature, and its intricate interplay factors hinder pinpointing a singular cause and thwart the quest for a cure. As an avenue towards potential intervention in ASD, this review will be exploring gene therapy. The research contrasts genetic with environmental approaches; it delves into current gene therapy studies examining both their positive and negative aspects while also considering emerging technologies. Gene therapy, despite its inherent challenges, emerges as a transformative intervention: it potentially yields a long-lasting impact on the cognitive dysfunction linked to ASD. The integration of CRISPR technology and personalized medicine--focusing on tailored interventions rooted in individual genetic profiles--offers promising avenues. Still, ethical considerations regarding genetic interventions demand an overarching approach that is both cautious and comprehensive. The findings not only emphasize the transformative potential of gene therapy, but also hint at its implications for precision treatments guided by CRISPR and personalized medicine; this research enriches existing discussions on ASD-specific gene therapy. Furthermore – steering future developments in a responsible manner necessitates an emphasis on ethical concerns associated with advancing such complex non-illness spectrum disorder treatments.